{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:00:16Z","timestamp":1758816016879},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Science Research and Innovation Fund","award":["R2566B056","R2566B056"],"award-info":[{"award-number":["R2566B056","R2566B056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00203-024-03950-4","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:02:07Z","timestamp":1713175327000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors"],"prefix":"10.1007","volume":"206","author":[{"given":"Anchalee","family":"Sistayanarain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duangkamol","family":"Kunthalert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"3950_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab474","author":"MJ Akiyama","year":"2021","unstructured":"Akiyama MJ, Riback L, Reeves JD et al (2021) Hepatitis C resistance-associated substitutions among people who inject drugs treated with direct-acting antiviral-containing regimens. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofab474","journal-title":"Open Forum Infect Dis"},{"key":"3950_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2036.2008.03763.x","volume":"28","author":"A Andriulli","year":"2008","unstructured":"Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S (2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28:397\u2013404. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03763.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3950_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","volume":"156","author":"TF Baumert","year":"2019","unstructured":"Baumert TF, Berg T, Lim JK, Nelson DR (2019) Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology 156:431\u2013445. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.024","journal-title":"Gastroenterology"},{"key":"3950_CR4","doi-asserted-by":"publisher","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","volume":"8","author":"A Bertoli","year":"2018","unstructured":"Bertoli A, Sorbo MC, Aragri M et al (2018) Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1\u20134 in Italy. Sci Rep 8:8988. https:\/\/doi.org\/10.1038\/s41598-018-26862-y","journal-title":"Sci Rep"},{"key":"3950_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","volume":"51","author":"PY Bochud","year":"2009","unstructured":"Bochud PY, Cai T, Overbeck K et al (2009) Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 51:655\u2013666. https:\/\/doi.org\/10.1016\/j.jhep.2009.05.016","journal-title":"J Hepatol"},{"key":"3950_CR6","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","volume":"218","author":"SM Borgia","year":"2018","unstructured":"Borgia SM, Hedskog C, Parhy B et al (2018) Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 218:1722\u20131729. https:\/\/doi.org\/10.1093\/infdis\/jiy401","journal-title":"J Infect Dis"},{"key":"3950_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/S-2007-1007262","volume":"15","author":"J Bukh","year":"1995","unstructured":"Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41\u201363. https:\/\/doi.org\/10.1055\/S-2007-1007262","journal-title":"Semin Liver Dis"},{"key":"3950_CR8","doi-asserted-by":"publisher","first-page":"8234","DOI":"10.1073\/pnas.90.17.8234","volume":"90","author":"J Bukh","year":"1993","unstructured":"Bukh J, Purcell RH, Miller RH (1993) At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci USA 90:8234\u20138238. https:\/\/doi.org\/10.1073\/pnas.90.17.8234","journal-title":"Proc Natl Acad Sci USA"},{"key":"3950_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.coviro.2018.10.005","volume":"32","author":"F Ceccherini-Silberstein","year":"2018","unstructured":"Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Crax\u00ec A (2018) Viral resistance in HCV infection. Curr Opin Virol 32:115\u2013127. https:\/\/doi.org\/10.1016\/j.coviro.2018.10.005","journal-title":"Curr Opin Virol"},{"key":"3950_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/hep4.1496","volume":"4","author":"MW Douglas","year":"2020","unstructured":"Douglas MW, Tay ESE, Wang DS et al (2020) Impact of an open access nationwide treatment model on hepatitis C virus antiviral drug resistance. Hepatol Commun 4:904\u2013915. https:\/\/doi.org\/10.1002\/hep4.1496","journal-title":"Hepatol Commun"},{"key":"3950_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL Recommendations on treatment of hepatitis C 2016. J Hepatol 66:153\u2013194. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.001","journal-title":"J Hepatol"},{"key":"3950_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Eng J Med 373:2608\u20132617. https:\/\/doi.org\/10.1056\/NEJMoa1512612","journal-title":"N Eng J Med"},{"key":"3950_CR13","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45\u2013S57. https:\/\/doi.org\/10.1016\/j.jhep.2014.07.027","journal-title":"J Hepatol"},{"key":"3950_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3851\/IMP3301","volume":"24","author":"Y Gozlan","year":"2019","unstructured":"Gozlan Y, Bucris E, Shirazi R et al (2019) High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data. Antivir Ther 24:221\u2013228. https:\/\/doi.org\/10.3851\/IMP3301","journal-title":"Antivir Ther"},{"key":"3950_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","volume":"68","author":"C Hezode","year":"2018","unstructured":"Hezode C, Reau N, Svarovskaia ES et al (2018) Resistance analysis in patients with genotype 1\u20136 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies. J Hepatol 68:895\u2013903. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.032","journal-title":"J Hepatol"},{"key":"3950_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/jmv.20561","volume":"78","author":"SS Hissar","year":"2006","unstructured":"Hissar SS, Goyal A, Kumar M et al (2006) Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 78:452\u2013458. https:\/\/doi.org\/10.1002\/jmv.20561","journal-title":"J Med Virol"},{"key":"3950_CR17","doi-asserted-by":"publisher","first-page":"9524","DOI":"10.1073\/pnas.87.24.9524","volume":"87","author":"N Kato","year":"1990","unstructured":"Kato N, Hijikata M, Ootsuyama Y et al (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524\u20139528. https:\/\/doi.org\/10.1073\/pnas.87.24.9524","journal-title":"Proc Natl Acad Sci USA"},{"key":"3950_CR18","doi-asserted-by":"publisher","first-page":"9437","DOI":"10.1007\/s11033-022-07803-5","volume":"49","author":"A Kiattanaphon","year":"2022","unstructured":"Kiattanaphon A, Vipsoongnern Y, Kunthalert D, Sistayanarain A (2022) Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a. Mol Biol Rep 49:9437\u20139443. https:\/\/doi.org\/10.1007\/s11033-022-07803-5","journal-title":"Mol Biol Rep"},{"key":"3950_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12985-015-0450-x","volume":"12","author":"K Kumthip","year":"2015","unstructured":"Kumthip K, Maneekarn N (2015) The role of HCV proteins on treatment outcomes. Virol J 12:217. https:\/\/doi.org\/10.1186\/s12985-015-0450-x","journal-title":"Virol J"},{"key":"3950_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.coviro.2014.04.012","volume":"8","author":"PJ Lim","year":"2014","unstructured":"Lim PJ, Gallay PA (2014) Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol 8:30\u201337. https:\/\/doi.org\/10.1016\/j.coviro.2014.04.012","journal-title":"Curr Opin Virol"},{"key":"3950_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/hep.27934","volume":"62","author":"E Lontok","year":"2015","unstructured":"Lontok E, Harrington P, Howe A et al (2015) Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62:1623\u20131632. https:\/\/doi.org\/10.1002\/hep.27934","journal-title":"Hepatology"},{"key":"3950_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv043","author":"A De Luca","year":"2015","unstructured":"De Luca A, Di Giambenedetto S, Lo Presti A et al (2015) Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofv043","journal-title":"Open Forum Infect Dis"},{"key":"3950_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","volume":"147","author":"DR McGivern","year":"2014","unstructured":"McGivern DR, Masaki T, Williford S et al (2014) Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147:453-462.e7. https:\/\/doi.org\/10.1053\/j.gastro.2014.04.021","journal-title":"Gastroenterology"},{"key":"3950_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894460","volume":"13","author":"S Mushtaq","year":"2022","unstructured":"Mushtaq S, Hashmi AH, Khan A, Asad Raza Kazmi SM, Manzoor S (2022) Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals. Front Pharmacol 13:894460. https:\/\/doi.org\/10.3389\/fphar.2022.894460","journal-title":"Front Pharmacol"},{"key":"3950_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JM, Lalezari JP et al (2015) All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61:1127\u20131135. https:\/\/doi.org\/10.1002\/hep.27726","journal-title":"Hepatology"},{"key":"3950_CR26","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","volume":"18","author":"G Nkontchou","year":"2011","unstructured":"Nkontchou G, Ziol M, Aout M et al (2011) HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 18:e516\u2013e522. https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01441.x","journal-title":"J Viral Hepat"},{"key":"3950_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1743-422X-9-245","volume":"9","author":"S Paolucci","year":"2012","unstructured":"Paolucci S, Fiorina L, Piralla A et al (2012) Naturally occurring mutations to HCV protease inhibitors in treatment-na\u00efve patients. Virol J 9:245. https:\/\/doi.org\/10.1186\/1743-422X-9-245","journal-title":"Virol J"},{"key":"3950_CR28","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1038\/s41598-017-15987-1","volume":"7","author":"S Paolucci","year":"2017","unstructured":"Paolucci S, Premoli M, Gulminetti R et al (2017) Baseline and breakthrough resistance mutations in HCV patients failing DAAs. Sci Rep 7:16017\u201316026. https:\/\/doi.org\/10.1038\/s41598-017-15987-1","journal-title":"Sci Rep"},{"key":"3950_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrgastro.2009.102","volume":"6","author":"JM Pawlotsky","year":"2009","unstructured":"Pawlotsky JM (2009) Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol 6:383\u2013385. https:\/\/doi.org\/10.1038\/nrgastro.2009.102","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3950_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky JM (2020) EASL Recommendations on treatment of hepatitis C: final update of the series. J Hepatol 73:1170\u20131218. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018","journal-title":"J Hepatol"},{"key":"3950_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1590\/S0074-02762012000200016","volume":"107","author":"A Peres-da-Silva","year":"2012","unstructured":"Peres-da-Silva A, Almeida AJ, Lampe E (2012) Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs. Mem Inst Oswaldo Cruz 107:254\u2013261. https:\/\/doi.org\/10.1590\/S0074-02762012000200016","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3950_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","volume":"18","author":"BE Pickett","year":"2011","unstructured":"Pickett BE, Striker R, Lefkowitz EJ (2011) Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 18:608\u2013618. https:\/\/doi.org\/10.1111\/j.1365-2893.2010.01342.x","journal-title":"J Viral Hepat"},{"key":"3950_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486\u2013504. https:\/\/doi.org\/10.1016\/j.jhep.2015.09.011","journal-title":"J Hepatol"},{"key":"3950_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C, Dvory-Sobol H, Svarovskaia ES et al (2016) Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151:501\u2013512. https:\/\/doi.org\/10.1053\/j.gastro.2016.06.002","journal-title":"Gastroenterology"},{"key":"3950_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijid.2020.03.061","volume":"95","author":"M Sayan","year":"2020","unstructured":"Sayan M, Y\u0131ld\u0131r\u0131m FS, Akhan S et al (2020) NS5A resistance-associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Int J Infect Dis 95:84\u201389. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.061","journal-title":"Int J Infect Dis"},{"key":"3950_CR36","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1099\/0022-1317-74-11-2391","volume":"74","author":"P Simmonds","year":"1993","unstructured":"Simmonds P, Holmes EC, Cha TA et al (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74:2391\u20132399. https:\/\/doi.org\/10.1099\/0022-1317-74-11-2391","journal-title":"J Gen Virol"},{"key":"3950_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith DB, Bukh J, Kuiken C et al (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318\u2013327. https:\/\/doi.org\/10.1002\/hep.26744","journal-title":"Hepatology"},{"key":"3950_CR38","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/hep.29837","volume":"69","author":"D Smith","year":"2019","unstructured":"Smith D, Magri A, Bonsall D et al (2019) Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 69:1861\u20131872. https:\/\/doi.org\/10.1002\/hep.29837","journal-title":"Hepatology"},{"key":"3950_CR39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12879-018-3356-6","volume":"18","author":"ME Soria","year":"2018","unstructured":"Soria ME, Gregori J, Chen Q et al (2018) Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 18:446. https:\/\/doi.org\/10.1186\/s12879-018-3356-6","journal-title":"BMC Infect Dis"},{"key":"3950_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N et al (2012) Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 54:352\u2013354. https:\/\/doi.org\/10.1016\/j.jcv.2012.04.024","journal-title":"J Clin Virol"},{"key":"3950_CR41","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.bj.2020.08.004","volume":"44","author":"MC Tsai","year":"2021","unstructured":"Tsai MC, Hung CH, Lu SN et al (2021) The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan. Biomed J 44:S126\u2013S131. https:\/\/doi.org\/10.1016\/j.bj.2020.08.004","journal-title":"Biomed J"},{"key":"3950_CR42","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/jac\/dkr581","volume":"67","author":"I Vicenti","year":"2012","unstructured":"Vicenti I, Rosi A, Saladini F et al (2012) Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 67:984\u2013987. https:\/\/doi.org\/10.1093\/jac\/dkr581","journal-title":"J Antimicrob Chemother"},{"key":"3950_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126764","volume":"10","author":"R Wasitthankasem","year":"2015","unstructured":"Wasitthankasem R, Vongpunsawad S, Siripon N et al (2015) Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS ONE 10:e012674. https:\/\/doi.org\/10.1371\/journal.pone.0126764","journal-title":"PLoS ONE"},{"key":"3950_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ejmech.2019.01.025","volume":"165","author":"M Zaj\u0105c","year":"2019","unstructured":"Zaj\u0105c M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jeli\u0144ska A (2019) Hepatitis C\u2014New drugs and treatment prospects. Eur J Med Chem 165:225\u2013249. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.025","journal-title":"Eur J Med Chem"},{"key":"3950_CR45","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem S, Mizokami M, Piankoet S et al (2017) NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol 66:910\u2013918. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.007","journal-title":"J Hepatol"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-024-03950-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-024-03950-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-024-03950-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T20:14:35Z","timestamp":1716063275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-024-03950-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3950"],"URL":"https:\/\/doi.org\/10.1007\/s00203-024-03950-4","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study protocols and procedures were approved by the Naresuan University Institutional Review Board (IRB No. P1-0134\/2565).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"215"}}